Author

Alicia Fravalo

Observed names: A Fravalo, A. Fravalo, Fravalo, Alicia

Institution: Cemka-Eval (France)

Observed institution: Cemka-Eval (France)

ORCID: 0009-0000-5202-6913

Observed ORCID: 0009-0000-5202-6913

OpenAlex ID: A5115636846

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019–2023)

2025 · E. Le Page, C. Emery, et al. · Revue Neurologique · 2

Outcomes of early-stage hepatocellular carcinoma patients treated by resection or ablation: real-life data from the French Administrative Health Care database

2026 · Marie Decraecker, Boris Guiu, et al. · Journal of Liver Cancer

1476P Survival and healthcare pathways of patients following resection or ablation for hepatocellular carcinoma in France: The ‘LIVERPOOL’ nation-wide study

2025 · J.F. Blanc, B. Guiu, et al. · Annals of Oncology

EE385 Economic Burden of Hepatocellular Carcinoma (HCC) Treated With a Curative Resection or Ablation (R/A) in France: Liverpool Study

2024 · C Le Dissez, P Nahon, et al. · Value in Health

Évolution de la prise en charge des patients atteints de la sclérose en plaques rémittente-récurrente et traités par natalizumab (TYSABRI, forme intra-veineuse et sous-cutanée) en France : une analyse du PMSI sur la période 2019/2022

2024 · Agathe Doutriaux, Corinne Emery, et al. · Revue Neurologique

Pollution lumineuse et risque du cancer du sein dans l’étude CECILE

2021 · Fravalo, Alicia, Godet, Kathleen, et al. · HAL

Works count: 6

Citation count: 2

H-index: 1

I10-index: